Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 10Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 4Breast Neoplasms 3Thyroid Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Pleural Effusion 1Peritoneal Neoplasms 1Neuroblastoma 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma, Follicular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 29Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × vandetanib × Clear all
NCT00752986 2016-12-05

ZACFAST

Sanofi

Phase 2 Terminated
39 enrolled 7 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00807170 2016-08-29

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

Sanofi

Phase 1 Terminated
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡